Clinicopathological and molecular features of DICER1-altered follicular-patterned differentiated high-grade thyroid carcinoma: a case series
This study characterizes a distinct molecular subgroup of differentiated high-grade thyroid carcinoma (DHGTC) driven by *DICER1* alterations, which are associated with follicular morphology, the absence of canonical MAPK drivers, and smaller tumor sizes compared to *DICER1*-wild-type cases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The thyroid is a small, butterfly-shaped gland in the neck that acts as the body's thermostat, releasing hormones that control how fast we burn energy. When this gland develops cancer, doctors usually categorize the tumors based on how the cells look under a microscope and how they behave. For a long time, the medical world divided these cancers into clear groups: some were slow-growing and easy to treat, while others were aggressive and dangerous. Recently, scientists have identified a new, tricky category called differentiated high-grade thyroid carcinoma. These tumors still look somewhat like normal thyroid tissue, but they are growing fast and causing damage, sitting in a gray area between the mild and the deadly forms. Understanding exactly what drives these specific tumors is crucial because it could change how doctors treat them, potentially moving away from a one-size-fits-all approach to something more precise.
A team of researchers at the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine in Nanjing set out to investigate a specific genetic clue within these aggressive tumors. They focused on a gene called DICER1, which acts as a master editor for the tiny instructions cells use to build proteins. When this gene is altered, it can disrupt how cells grow and divide. The scientists gathered ten cases of these high-grade thyroid cancers that had been diagnosed at their hospital between 2018 and 2026. They carefully re-examined the tissue samples to confirm the diagnosis, separating them into two groups based on their shape and behavior: those that looked more like the newly defined high-grade type and those that fit the older definition of poorly differentiated cancer. Using advanced sequencing technology, they read the genetic code of the tumors to see if the DICER1 gene was broken or changed in any of them.
The study revealed a striking pattern. Out of the eight tumors that fit the high-grade definition, four were found to carry alterations in the DICER1 gene. None of the two tumors classified as the older, poorly differentiated type showed these changes. This suggests that the DICER1 alteration is not a random accident but a specific feature of a particular subgroup of these aggressive cancers. The researchers noticed that every single tumor with this genetic change had a distinct shape, growing in clusters that resembled tiny follicles, much like the normal structure of the thyroid gland. In contrast, the tumors without this genetic change looked different, often appearing more solid or disorganized. Furthermore, the tumors with the DICER1 alteration did not carry the common genetic drivers usually found in thyroid cancer, such as specific changes in the BRAF or RAS genes, which are often the primary suspects in other thyroid cancers.
Beyond just the genetic code, the researchers found that the physical characteristics of these tumors differed significantly. The tumors carrying the DICER1 alteration were noticeably smaller than those without it. On average, the altered tumors measured about 2.15 centimeters across, while the unaltered ones were much larger, with a median size of 5.0 centimeters. The larger tumors were also more likely to have invaded nearby blood vessels or spread outside the thyroid gland, whereas the smaller, altered tumors had not shown these signs of spreading in the cases studied. In one specific case where the researchers compared the main tumor to a cancer cell that had traveled to a nearby lymph node, they found that the genetic change was present in both, but a secondary genetic tweak was only found in the main tumor. This indicates that even within a single patient, different parts of the cancer can have slightly different genetic makeups, a detail that could matter for future treatments.
The findings point to a new way of thinking about these aggressive thyroid cancers. Instead of viewing them all as a single, chaotic group, the data suggests that there is a distinct molecular subgroup defined by the DICER1 gene change. These tumors seem to follow a different path of development, one that starts with a specific genetic error and maintains a follicular shape even as the cancer becomes more aggressive. While the study is small and the researchers cannot yet say for certain how this affects a patient's long-term survival, the discovery provides a clear target for future investigation. It offers a potential explanation for why some high-grade thyroid cancers look and behave differently from others, hinting that the key to understanding their evolution lies in the specific way the DICER1 gene is altered. This work does not solve the problem of treating these cancers immediately, but it draws a clearer map of the territory, showing scientists exactly where to look next.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.